Abstract: 【Abstract】 Currently, childhood atopic dermatitis （AD） is mainly treated by regular use of moisturisers in combination with topical glucocorticoids or calcineurin inhibitors. For some children with refractory moderate-to-severe AD, systemic glucocorticoids or off-label use of other immunomodulators may be required; however, these treatments usually have some limitations and adverse effects. In recent years, with the discovery of key inflammatory factors in AD, dupilumab, a biological agent targeting interleukin-4/13, has been widely used in clinical practice, and shown certain efficacy. This review summarizes recent clinical studies on dupilumab in the treatment of AD in children.

Key words: Dermatitis, atopic, Child, Therapy, Biological agents, Dupilumab